Actively Recruiting
Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML
Led by The First Affiliated Hospital of Xiamen University · Updated on 2025-02-24
30
Participants Needed
1
Research Sites
93 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To investigate the safety and efficacy of the CVA regimen, composed of Chiglitazar Sodium in combination with Venetoclax and Azacitidine, in the treatment of patients with refractory/relapsed acute myeloid leukemia (R/R AML).
CONDITIONS
Official Title
Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of acute myeloid leukemia (AML) that is relapsed or refractory
- Age 18 years or older, male or female
- Expected survival longer than 3 months
- Creatinine clearance of 50 mL/min or higher
- Liver enzymes (AST and ALT) less than or equal to 3 times the upper limit of normal, unless due to leukemia involvement
- Bilirubin less than or equal to 3 times the upper limit of normal, unless due to leukemia involvement
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
- Not pregnant and using contraception during treatment
- Able to understand and willing to give informed consent
You will not qualify if you...
- Diagnosis of acute promyelocytic leukemia (APL)
- Active central nervous system leukemia
- Significant heart problems such as prolonged QTc interval (males >450 ms, females >470 ms), ventricular tachycardia, atrial fibrillation, second-degree heart block, recent heart attack or congestive heart failure within the past year, or symptomatic coronary heart disease requiring medication
- Active, uncontrolled severe infection
- Other non-myeloid cancers within the past 2 years
- Mental health disorders that prevent participation
- Previous solid organ transplant (except stem cell transplant if no graft-versus-host disease or immunosuppressive treatment ongoing)
- Any other condition that the investigator believes makes participation unsuitable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China, 361000
Actively Recruiting
Research Team
B
Bing Xu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here